Drug – bio-affecting and body treating compositions – Extract or material containing or obtained from a...
Reexamination Certificate
2011-02-08
2011-02-08
Afremova, Vera (Department: 1657)
Drug, bio-affecting and body treating compositions
Extract or material containing or obtained from a...
C424S094610, C424S439000
Reexamination Certificate
active
07883708
ABSTRACT:
A novel substance that has the physiological activity of the aglycone of isoflavones and the physiological activity of the culture of the basidiomycetes with the physiological activities being synergistically enhanced, obtained by cultivating a basidiomycetes having a β-glucosidase activity in a medium containing an isoflavone, a method for producing it, and food, feedstuff and medicine containing it.The substance of the invention is improved in the physiological effect of the aglycone of isoflavones and the physiological effect of the culture of the basidiomycetes, and is not only useful as an anti-tumor agent but also is useful for therapy and/or prevention of osteoporosis and also as an immune enhancement agent.
REFERENCES:
patent: 4461760 (1984-07-01), Sugano et al.
patent: 5455171 (1995-10-01), Yanni et al.
patent: 5503647 (1996-04-01), Dahlberg et al.
patent: 5763389 (1998-06-01), Shen et al.
patent: 59-41302 (1984-03-01), None
patent: 1-258669 (1989-10-01), None
patent: 5-170756 (1993-07-01), None
patent: 6-178616 (1994-06-01), None
patent: 8-214787 (1996-08-01), None
patent: 11-89589 (1999-04-01), None
patent: WO-91/00002 (1991-01-01), None
patent: WO-95/10530 (1995-04-01), None
patent: WO-99/48386 (1999-09-01), None
Wei et al. Proceedings of the Society for Experimental Biology and Medicine. 1995, vol. 208, No. 1, pp. 124-130.
Barnes, Stephen, et al., “Biochemical Targets of the Isoflavone Genistein in Tumor Cell Lines,” Proceedings of the Society for Experimental Biology & Medicine, vol. 208, No. 1, pp. 103-108, XP-000918092, 1998.
Choi et al., “p53-Independent Induction of P21 (Waf1/Cip10, Reduction of Cyclin B1 and G2/M Arrest by the Isoflavone Genistein in Human Prostate Carcinoma Cells,” Jpn. J. Cancer Res., (2000), 91:164-173.
Coward, Lori, et al., “Genistein, Daidzein, and Their β-Glycoside Conjugates: Antitumor Isoflavones in Soybean Foods from American and Asian Diets,” Journal of Agricultural and Food Chemistry, American Chemical Society, vol. 41, No. 11, pp. 1961-1967, XP 002028058, Nov. 1, 1993.
English Language Abstract of JP Publication No. 10 075739, Patent Abstracts of Japan, vol. 1998, No. 08, published Mar. 24, 1998.
English Language Abstract of JP Publication No. 56 068364, Patent Abstracts of Japan, vol. 005, No. 132, published Jun. 9, 1981.
English Language Abstract of JP Publication No. 61 009280, Patent Abstracts of Japan, vol. 010, No. 148, published Jan. 16, 1986.
English Language Abstract of JP Publication No. 61 040786, Patent Abstracts of Japan, vol. 010, No. 199, published Feb. 27, 1986.
English Language Abstract of JP Publication No. 63 208533, Patent Abstracts of Japan, vol. 012, No. 496, published Aug. 30, 1988.
Gan et al., “Medication of the Cytotoxicity of Lanostanoids and Steroids ofGanoderma tsugaeThrough Apoptosis and Cell Cycle,” J. Nat. Prod., (1998) 61:485-487.
Matsuda, S. et al.,Hydrolysis of Isoflavones in Soybean Cooked Syrup by Lactobacillus casei subsp. rhamnosus IFO 3424, J. Fermentation Bioengineering, (1992), pp. 301-304, vol. 74, No. 5.
Matsuyama, J. et al.,Hydrolytic Profiles of Soybean Isoflavone Glycoside with β-Glycosidases in the Cultures of Bifidobacteria and Lactic Acid Bateria, Tamagawa Daigaku Kenkyu Houkoku, (1990), pp. 33-42, vol. 30, part of p. 39.
Messina, Mark J., et al., “Soy Intake and Cancer Risk: A Review of the In Vitro and In Vivo Data,” Nutrition and Cancer, vol. 21, No. 2, pp. 113-131, XP008009192, 1994.
Park, et al., Phytochemistry, May 1999, 51(1):147-151.
Sripuan et al., J. Sci. Fac. CMU, (1999) 26(2):59-64.
Tsuzaki, S. et al., New Food Industry, (1998), pp. 59-64, vol. 40, No. 4, Section 2 on pp. 59-60.
Yun, Taik-Koo, “Update from Asia—Asian Studies on Cancer Chemoprevention,” Annals of the New York Academy of Sciences; Cancer Prevention—Novel Nutrient and Pharmaceutical Developments, pp. 157-192, XP009029523, 1999.
Zhou et al., “Inhibition of Murine Bladder Tumerigenesis by Soy Isoflavones Via Alterations in the Cell Cycle, Apoptosis, and Angiogenesis,” Cancer Research, (1998) 58:5231-5238.
Jakucs, E., et al., “Some Characteristics and Partial Purification of theGanoderma lucidumCellulase System,” Acta Microbiologica et Immunologica Hungarica, 1994, vol. 41, pp. 23-31.
Duran, N., et al., “A new alternative process for Kraft effluent treatment,” Biodegradation, 1994, vol. 5, pp. 13-19.
Kosuna Ken-ichi
Miura Takehito
Sun Buxiang
Yuan Lan
Afremova Vera
Amino Up Chemical Co. Ltd.
Finnegan Henderson Farabow Garrett & Dunner LLP
LandOfFree
Substance derived from basidiomycetes culture, method for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substance derived from basidiomycetes culture, method for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substance derived from basidiomycetes culture, method for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635705